metsera glp 1 Reports Highly Competitive Results from Ongoing Trial of Novel, Potential Once-Monthly Injectable GLP-1 Receptor Agonist MET-097 Pfizer acquires Metsera and its

Name: metsera glp 1 Reports Highly Competitive Results from Ongoing Trial of Novel, Potential Once-Monthly Injectable GLP-1 Receptor Agonist MET-097 Pfizer acquires Metsera and its
Brand: www.allread.ai
SKU: 30736694106
Price: 20.16 USD
Availability: InStock
Rating: 4.1251 (22 reviews)

SKU: 30736694106

4.1

USD20.16 USD58.16

Pay in 4 interest-free payments of $5.04 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Live Spec

Pfizer acquires Metsera and its GLP 1 candidates in new $4.9bn obesity play News European Pharmaceutical Review Pfizer Strengthens Obesity Foothold With Metsera Acquisition Pfizer Finalizes up to $10B Acquisition of Metsera after Fierce Bidding War with Novo Nordisk: A Strategic Leap in GLP 1 Therapeutics Pharmacally Pfizer boosts weight loss pipeline with GLP 1 drug Drug Discovery World (DDW) 10 K Pfizer's new prize Metsera touts 14.1% weight loss for GLP 1

Store: www.allread.ai · Domain: www.allread.ai

Description

This result is consistent with another study

This is thought to be related to GLP-1s effects on the brains dopamine reward pathway, says Nitya Kumar, MD, an endocrinologist and an assistant professor of medicine at the Duke University School of Medicine in Durham, North Carolina

Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide